Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Genomic and transcriptomic correlates of deep prostate-specific antigen response in patients with metastatic androgen pathway modulation-sensitive prostate cancer. | Oncologist | 2026 | 42752828 | PubTator, text mining | PubMed |
| Sortase-mediated generation of various macrocyclic peptide scaffolds from low-reactivity electrophilic substrates. | Chem Sci | 2026 | 42746122 | PubTator, text mining | PubMed |
| Comparative Transcriptomic and Immune Profiling Reveals a Shared Molecular Identity Between Clear Cell Odontogenic Carcinoma and Hyalinizing Clear Cell Carcinoma. | Mol Cancer Res | 2026 | 42743086 | PubTator, text mining | PubMed |
| Anti-Trop2-Guided Liposomes Restore Methotrexate Sensitivity in Chemoresistant Gestational Trophoblastic Neoplasia. | Int J Nanomedicine | 2026 | 42740940 | PubTator, text mining | PubMed |
| Clinicopathological and Prognostic Significance of TROP2 and HER3 Expression in Early-Stage Cervical Carcinoma. | Diagnostics (Basel) | 2026 | 42739301 | PubTator, text mining | PubMed |
| Antibody-Mediated Therapies in Urothelial Carcinoma: A Critical Narrative Review. | Cancers (Basel) | 2026 | 42738266 | PubTator, text mining | PubMed |
| T-Cell Engagers in Lung Cancer: A Comprehensive Literature Review from Tarlatamab Approval to Next-Generation Strategies. | Cancers (Basel) | 2026 | 42738247 | PubTator, text mining | PubMed |
| SCLC TumorMiner: A genomics platform for small cell lung cancer precision oncology. | iScience | 2026 | 42733745 | PubTator, text mining | PubMed |
| Exposure-Response Analyses of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Advanced Non-small Cell Lung Cancer. | Clin Pharmacol Ther | 2026 | 42733211 | PubTator, text mining | PubMed |
| Disease stage-dependent expression of ADC-related biomarkers in urothelial carcinoma. | Transl Androl Urol | 2026 | 42729159 | PubTator, text mining | PubMed |
| Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment. | Biochim Biophys Acta Rev Cancer | 2026 | 42727894 | PubTator, text mining | PubMed |
| Datopotamab deruxtecan in breast cancer treatment: a systematic review of clinical efficacy and safety. | Front Immunol | 2026 | 42723854 | PubTator, text mining | PubMed |
| Target Antigen Identification for Antibody Drug Conjugate Therapy in Biliary Tract Cancer. | Clin Cancer Res | 2026 | 42720429 | PubTator, text mining | PubMed |
| Efficacy and Safety of Sacituzumab Govitecan for Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs). | Am J Clin Oncol | 2026 | 42715490 | PubTator, text mining | PubMed |
| TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy. | Sci Adv | 2026 | 42715334 | PubTator, text mining | PubMed |
| Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study. | Breast Cancer Res Treat | 2026 | 42714605 | PubTator, text mining | PubMed |
| Innovative pathological and therapeutic approaches for poorly cohesive gastric cancer. | Front Oncol | 2026 | 42713041 | PubTator, text mining | PubMed |
| Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors. | J Hematol Oncol | 2026 | 42711696 | PubTator, text mining | PubMed |
| TROP2 Expression in Bladder Transurethral Resection Specimens: Correlation With Histological Grade and Survival. | In Vivo | 2026 | 42665429 | PubTator, text mining | PubMed |
| Potent antitumor efficacy of datopotamab deruxtecan compared with sacituzumab govitecan in an intracranial tumor model of triple-negative breast cancer. | Mol Cancer Ther | 2026 | 42661416 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=2